iPierian’s efforts are centered on applying its technology to diseases for which there are poor in vivo and in vitro models and limited therapeutic treatments to date. iPierian’s proprietary programs are initially focused on three neurological diseases, including Parkinson’s disease, spinal muscular atrophy and amyotrophic lateral sclerosis. These conditions have limited therapeutic treatments, and scientists have demonstrated the ability to differentiate the affected cell types in these disorders.
iPierian is also working on calcific aortic valve disease, through its collaboration with the Gladstone Institute of Cardiovascular Disease, and plans to expand further into cardiovascular and metabolic diseases through additional collaborations with pharmaceutical partners.
